European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- !!hot!!

European Pharmacopoeia (Ph. Eur.) Monograph 0478: Tablets

Guide to Ph. Eur. Monograph 0478: Tablets

Upcoming in Ph. Eur. 12.0 (2025):

• In-silico dissolution predictions: Encouragement of PBPK modeling as a surrogate for dissolution in certain post-approval changes.
• Process Analytical Technology (PAT): Guidelines for real-time release testing (RTRT) using NIR spectroscopy as an alternative to offline testing for uniformity.

2. Definition

Under Monograph 0478, tablets are defined as "solid preparations each containing a single dose of one or more active substances." They are obtained by compressing uniform volumes of particles or by other methods of manufacture (e.g., moulding, extrusion).

The monograph recognizes tablets as the most widely used dosage form due to their stability, ease of administration, and accurate dosing. Tablets are intended for oral administration, though the monograph notes that some may be prepared for use in other routes (e.g., vaginal) or to achieve specific release profiles. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Key Changes in Ph. Eur. 11.3 (2023):

• Renewed focus on "Orodispersible tablets": Defined disintegration time strictly as ≤ 180 seconds in a validated oral cavity simulation apparatus.
• Addition of "Multilayer tablets": Explicit guidance for delamination testing (tensile strength between layers must be > 1.5 MPa).
• 3D-printed tablets: New text allowing for additive manufacturing provided that mass uniformity and dissolution meet conventional criteria.

4. Categorization of Tablets

Monograph 0478 classifies tablets based on their release characteristics and site of action: European Pharmacopoeia (Ph

4.1. Appearance

• Visual inspection: homogeneous, free from cracks, chips, or sticking.
• For coated tablets: smooth, uniform coating.

Quick reference checklist for QC and regulatory teams

• Confirm applicable tablet type and whether 0478 applies.
• Verify API identity and assay methods are per API monograph.
• Select/validate dissolution and disintegration methods suitable for formulation.
• Decide weight variation vs. content uniformity testing based on dose and solubility.
• Validate analytical methods (stability-indicating).
• Define impurity limits and conduct forced-degradation studies.
• Ensure packaging and storage claims are supported by stability data.
• Maintain GMP documentation and batch records aligned with monograph expectations.

Hardness (Crushing Strength)

While not always a specific limit in the monograph, hardness is a critical in-process control (IPC). The tablet must be hard enough to handle but soft enough to disintegrate/dissolve. Visual inspection: homogeneous

• Home
• General
• Guides
• Reviews
• News